Sandoz in Africa - a global leader
-
Upload
pharmaafrica -
Category
Health & Medicine
-
view
557 -
download
2
description
Transcript of Sandoz in Africa - a global leader
Sandoz - A Global Leader
March 2013
Nick Haggar Head Sandoz Africa, Middle East and Western Europe
This is the first dummy chapterSandoz a Global Leader
2 | Together Growing Faster - Sandoz and Celesio | October 10th, 2012
Environment Patient needs Novartis portfolio
Sandoz is a Novartis Group Company
2011 salesUSD billion
Full rangeof healthcareoptions
Innovative medicines
Prevention
Affordable options
Self-care
Pharmaceuticals
Sandoz – Generics
Consumer Health (OTC, Animal Health)
Vaccines and Diagnostics
Eye Care (Alcon, CIBA VISION)
32.5
9.5
4.6
2.0
10.0
Novartis’ mission is to care for and cure patients
In 2011, Novartis treated and protected more than 1 billion patients
around the world with our products and Sandoz medicines reached over
400 million patients
Sandoz is a global leader in generics
1 Pro forma by including all acquired companiesNote: Figures reflect sales and ROS for generics business only, including API and excluding originator (e.g. Copaxone) and proprietary business (e.g. Women’s Health) Note: All trademarks, logos and pictures are the property of the respective ownerSource: Company annual and quarterly reports, except Actavis figures estimated based on IMS
2011 generics sales1
USD million
2,432
2,273
10,196
3,320
2,313
9,473
2,358
5,559
2,126
1,876
Present in 140 countries
~25,000 employees worldwide
Portfolio of ~1,100 compounds and >23,500 SKUs
Rich pipeline with >800 projects
Leader in differentiated generics
Biosimilars pioneer
Sandoz operates in 140 countries globally
Subsidiaries
Representative offices
* Sample Sandoz manufacturing and development sites.
Production*
Development*
Wilson
Cambe/ Taboao
Buenos Aires
Gebze Turbhe
Strykow
Zhongshan
Kaminoyama
Barleben
Boucherville
Broomfield
Unterach
Kalwe
Holzkirchen Rudolstadt
Kundl / Schaftenau
Ljubljana / Mengeš
Spartan Jakarta
Candelaria
Sandoz has an industry-leading breadth of technologies
Inhalers
Patches/transdermals/ thin films
Innovativesolid formulations
Implants
Biosimilars
APICytotoxics
Hormones
Lyophilization
Injectables
Ophthalmics
Dermatology
Anti-Infectives: Sandoz is the leading Gx player
GlaxoSmithKline
0.7Bayer
Medicis 0.8
Daiichi Sankyo 2 0.9
Johnson & Johnson 1.0
Merck & Co. 1.2
Teva 1.3
Sanofi 2 1.3
Sandoz 1.7
1.7
Pfizer 3.7
Total anti-infectives sales USD bn (FY 2011)
-6%
-4%
-5%
-5%
-2%
+4%
-8%
-12%
+22%
-25%
CAGR1 Percent (2009-11)
Source: IMS, global market, anti-infectives defined as J1 (antibacterials)
GxOriginator
1 Growth rate at constant currency rate2 Incl. Generic business
This is the first dummy chapterSandoz in Africa
Commitment and Growth in Africa
Minister of Industry and Trade, Egypt
World Economic Forum, Addis Ababa
Minister of Health, Ethiopia
AU-UNIDO Conference on Diversified Economy and Manufacturing, Addis Ababa
Wide range of bilateral meetings
•4 Ministers
•7 NGOs (Bill & Melinda Gates Foundation, Director-General of Red Cross, ...)
•Private companies (Philips, Coca Cola, Merck, ...)
•Development organizations (GIZ, US African Development Foundation, ...)
Wide range of bilateral meetings
•Local manufacturers from Ethiopia, Kenya, Botswana, Sierra Leone, ...
•UN, WHO, GIZ, British Embassy, German Embassy, Swiss Embassy
5 joint projects to improve patient’s life - Zambia Example
Cardiovascular Academy
Rheumatic Heart
Disease
Health shops
Build high quality, affordable portfolio
Zambora Project
Focus Areas
Quality
Regulatory
Distribution
Affordability
Partnerships
REGIONAL FOCUS: GROWTH OPPORTUNITIES FOR PHARMA COMPANIES
IN THE WEST AFRICAN MARKET DR YAW ADU GYAMFI, CEO, DANADAMS PHARMACEUTICAL INDUSTRIES
NICK HAGGAR, HEAD, WESTERN EUROPE, MIDDLE EAST & AFRICA, SANDOZ
MODERATOR: DR VINCE S. THOMAS, MANAGING DIRECTOR, V.S THOMAS GLOBAL HEALTH STRATEGY CONSULTING